Icon

LEVAQUIN (nda020634)- (250MG,500MG,750MG)

LEVOFLOXACIN JANSSEN PHARMS
250MG,500MG,750MG
Yes No
2011-Jun-20 Expired
None None
None No
LEVAQUIN® is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria.  Pneumonia: Nosocomial and Community Acquired  Skin and Skin Structure Infections: Complicated and Uncomplicated  Chronic bacterial prostatitis  Inhalational Anthrax, Post-Exposure  Plague  Urinary Tract Infections: Complicated and Uncomplicated  Acute Pyelonephritis  Acute Bacterial Exacerbation of Chronic Bronchitis  Acute Bacterial Sinusitis
14 2 8
Total Other Developers None
Drugs with Suitability No
250MG ** ** - 5 1
500MG ** ** - - 5
750MG ** ** - 5 1
NDA Sales Available Total Generic Sales Available
No 7
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ** ****** **** *** **. *****'* ************ ******* *********** ****** **. **, ** ****, ** **** & ** ****, ********** ******* *** ******, *******-********** ********,, *******-**********, ********* ******, ***** (***) ***
****** ****** *** *.*. *********** ********** ***** **, *********, - ****, ******** (***) ***
****** ***** ************ ***** ************ ******* *********** ****** **. ***, *** & ***, ******* ***** ******** ******* ** * *, *******-*******, ***-******, ****. - *********, *********, ******* ******, ***** (***) ***
****** ***** ***** ******* *********** **** **. **-*, ***** *-*, ***** ********** ****, *****, ********, *** ******, ***** (***) ***
****** ******** ****** *** ******** *************** ******* *********** ******* *****, **** ****** **********,****** *****, ******** *****, ******** ******* ******, ***** (***) ***
****** ********* ****** *** ******** ****** *** *********** **** ***** *** *****, ******, *** ****** (**) *****, ****** ****** (***) ***
****** ********* ****** *** *** ********** ******* *********** ****-*, **. **. ***/*, ***/*, ***/*, **** **. *-*/*, ***** ***, ***** ********** ****, ********* (*******), ********* (******), ************ (********), ************, ********* ******, ***** (***) ***
****** ********* ****** *** ********* ****** ******* *********** ****-***, ** **. ***/*, ***/*, ***/*, ***/* & ***/*, **** ** **** ***, *****, ***** ********** ****, *********, ********* ******, ************, ********* ******, ***** (***) ***
****** ****** **** *** * ****** **** ******* *********** **** *, **. **.: ***, ***, *** & ***, ***** *********** ***, ********* *******, ************, ********* ******, ***** (***) ***
****** **** **** ************** ********** ***. *********** ** *** ******* ******, ********** ****, **** ****, *******, ****** (***) ***
****** ********* ********* ***** ******* *********** **** ** ****, *-*** ** *-***, *-*** ** *-***, **** ** *-***/*/*/*, *-****, *-***, *-***, *-***, ***** ********** ****, ********, *** ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.